Show simple item record

dc.contributor.authorBarrie, Nicola
dc.date.accessioned2019-10-03T04:37:53Z
dc.date.available2019-10-03T04:37:53Z
dc.date.issued2019-04-18
dc.identifier.urihttp://hdl.handle.net/2123/21185
dc.description.abstractChronic inflammatory joint disease represents an emerging public health issue, occupying a sizeable proportion of the adult population in the industrialized world. Recently, there has been a resurgence of interest in marijuana and its natural and synthetic derivatives, cannabinoid receptor agonists and antagonists, as well as chemically related compounds, for their therapeutic potential as both an anti-inflammatory and analgesic. Whilst the benefits of endocannabinoid-based treatments appear promising, very few studies have investigated the use of the self-assembled nanoparticles (NPs) for targeted drug delivery. In this study, the nanostructure mesophase behaviour of a series of mixed monoethanolamide lipids of oleoylethanolamide (OEA) and linoylethanolamide (LEA) into higher order NP structures for the encapsulation and delivery of drugs was investigated. In addition to drug encapsulation, active targeting through the conjugation of a synovium-targeting peptide, HAP-1, to the surface of these NP’s was used to facilitate selective accumulation of therapeutic agents the inflamed joint. The inhibitory cytokine effects of these targeted NPs was demonstrated in vitro, and in vivo using an adjuvant induced arthritis model of inflammation. The ability to deliver endocannabinoid based NPs to specific sites of the body mediating pharmacological endocannabinoid-like effects to influence key physiological pathways, provides a novel drug delivery system and medicinal potential to treat many diseases in many fields of medicine in which inflammation is a key feature of the disease.en_AU
dc.publisherUniversity of Sydneyen_AU
dc.publisherFaculty of Medicine and Healthen_AU
dc.publisherDepartment of Rheumatologyen_AU
dc.publisherWestmead Clinical Schoolen_AU
dc.rightsThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en_AU
dc.subjectNanoparticleen_AU
dc.subjectDrug-deliveryen_AU
dc.subjectArthritisen_AU
dc.subjectInflammationen_AU
dc.subjectEndocannabinoiden_AU
dc.subjectPeptide-conjugateden_AU
dc.titleENDOCANNABINOID-BASED NANOPARTICLES TARGETED TO THE SYNOVIUM FOR THE TREATMENT OF ARTHRITISen_AU
dc.typePhD Doctorateen_AU
dc.type.pubtypeDoctor of Philosophy Ph.D.en_AU


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record